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Abstract
Background: Probucol, a cholesterol-lowering agent that paradoxically also lowers high-density lipoprotein
cholesterol has been shown to prevent progression of atherosclerosis. The antiplatelet agent cilostazol, which has
diverse antiatherogenic properties, has also been shown to reduce restenosis in previous clinical trials. Recent
experimental studies have suggested potential synergy between probucol and cilostazol in preventing
atherosclerosis, possibly by suppressing inflammatory reactions and promoting cholesterol efflux.
Methods/design: The Synergistic Effect of combination therapy with Cilostazol and probUcol on plaque
stabilization and lesion REgression (SECURE) study is designed as a double-blind, randomised, controlled,
multicenter clinical trial to investigate the effect of cilostazol and probucol combination therapy on plaque volume
and composition in comparison with cilostazol monotherapy using intravascular ultrasound and Virtual Histology.
The primary end point is the change in the plaque volume of index intermediate lesions between baseline and 9-
month follow-up. Secondary endpoints include change in plaque composition, neointimal growth after
implantation of stents at percutaneous coronary intervention target lesions, and serum levels of lipid components
and biomarkers related to atherosclerosis and inflammation. A total of 118 patients will be included in the study.
Discussion: The SECURE study will deliver important information on the effects of combination therapy on lipid
composition and biomarkers related to atherosclerosis, thereby providing insight into the mechanisms underlying
the prevention of atherosclerosis progression by cilostazol and probucol.
Trial registration number: ClinicalTrials (NCT): NCT01031667
Background
The benefit of reducing low-density lipoprotein (LDL)
cholesterol in the management of coronary artery dis-
ease (CAD) has been demonstrated in various large-
scale randomized clinical trials [1]. These trials have
shown that statin therapy, which is currently considered
an essential element in CAD treatment regimens, does
improve clinical outcomes, but is only able to prevent
coronary events in less than 30% of patients. Therefore,
a need remains for new and more effective cardiovascu-
lar drug therapies.
Probucol, a mild cholesterol-lowering agent with anti-
oxidant and anti-inflammatory properties, has been
shown to reduce atherosclerosis and prevent restenosis
after percutaneous coronary intervention (PCI) [2].
* Correspondence: whshim@yuhs.ac
† Contributed equally
1Severance Cardiovascular Hospital, Yonsei University Health System, Seoul,
Korea
Full list of author information is available at the end of the article
Ko et al. Trials 2011, 12:10
http://www.trialsjournal.com/content/12/1/10 TRIALS
© 2011 Ko et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
However, probucol also causes a remarkable reduction
in high density lipoprotein (HDL) and prolongation of
QT intervals on electrocardiograms, side effects that
have led to the withdrawal of probucol from the market
in many countries. Although the mechanisms underlying
the antiatherosclerotic effect of probucol remain unclear,
previous speculation has centered on inhibition of oxi-
dative modification of LDL cholesterol [3]. However,
recent studies have suggested that enhanced reverse
cholesterol transport caused by activation of cholesteryl
ester transfer protein (CETP) and scavenger reverse cho-
lesterol class B type 1 (SR-B1) is the major mechanism
responsible for both the antiatherogenic effect and
reduction of HDL levels by probucol [4-6]. The apparent
lowering of HDL levels by probucol may be related to a
change in the composition of HDL subtypes, including
an increase in preb1-HDL ("lipid-poor” apoA-1), that
participate in the cholesterol efflux [7]. Therefore, the
lowering of HDL by probucol is not a side effect, per se,
but instead may reflect its main effect of increasing cho-
lesterol efflux. Furthermore, probucol has been shown
to inhibit mononuclear cell adhesion and reduce expres-
sion of vascular cell adhesion molecule (VCAM) [8].
Probucol also promotes nitric oxide-mediated vasodila-
tation and re-endothelialization, and inhibits smooth
muscle cell proliferation [9].
Cilostazol, an inhibitor of type 3 phosphodiesterase
that exerts antiplatelet activity through suppression of
cyclic adenosine monophosphate degradation [10], also
exhibits diverse antiatherogenic properties. Studies have
shown that cilostazol improves endothelial function by
increasing nitric oxide production [11], promotes
scavenging of free radicals [12], and inhibits foam cell
formation [13] and smooth muscle cell proliferation
[14]. In addition, cilostazol has been shown to decrease
triglyceride concentrations and increase HDL cholesterol
concentration, possibly by increasing the activity of lipo-
protein lipase [15,16].
A previous study by Sekiya et al. [17] reported that
cilostazol and probucol combination therapy reduced
restenosis after stent implantation more effectively than
did either cilostazol or probucol alone. In addition,
recent studies have demonstrated potential synergistic
effects of cilostazol and probucol used in combination
in the prevention of atherosclerosis [18,19]. Yoshikawa
et al. [18] found that combined administration of cilos-
tazol and probucol induced a greater decrease in the
atherosclerotic lesion area in LDL receptor-deficient
mice than did administration of each drug separately.
Park et al. [19] showed that cilostazol and probucol
combination therapy inhibited the expression of VCAM-
1 and monocyte chemoattractant protein-1 (MCP-1)
more effectively than did either cilostazol or probucol
monotherapy.
Intravascular ultrasound (IVUS) is a useful imaging
modality for assessment of atherosclerotic plaque and
vessel wall morphology. Especially, Virtual histology
(VH) IVUS (Volcano Therapeutics, Inc., Rancho Cor-
dova, California) using spectral analysis of the radiofre-
quency ultrasound back-scatter signals allows
identification and relative quantification of four different
components of atherosclerotic plaques: fibrous, fibro-
fatty, dense calcium and necrotic core [20-25]. Therefore,
the SECURE study is designed to investigate effects of
cilostazol and probucol combination therapy on coronary
plaque volume and composition using VH-IVUS in com-
parison with cilostazol monotherapy.
Methods/design
Study Design
This is a double-blind, placebo-controlled, randomised,
multicenter clinical trial to evaluate the efficacy of pro-
bucol and cilostazol combination therapy compared
with cilostazol alone in the prevention of coronary pla-
que progression (Figure 1). A total of 118 patients (see
Sample size calculation, below) will be enrolled at five
PCI centers in Korea. After enrollment and baseline
investigation with IVUS and VH to establish index non-
PCI target intermediate lesions and stented PCI target
lesions, patients will be evaluated in clinical follow-up
visits at 1, 3, 6, and 9 months. In the final 9-month fol-
low-up examination, patients will be evaluated by IVUS
and VH to assess plaque volume and plaque composi-
tion in index non-PCI target intermediate lesions, and
measure neointimal hyperplasia in index stented PCI
Figure 1 SECURE study algorithm. PCI, percutaneous coronary
intervention; DM, diabetes mellitus; VH-IVUS, Virtual Histology
intravascular ultrasound; MI, myocardial infarction; TVR, target vessel
revascularization; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; hsCRP, high-sensitivity C-reactive protein; VCAM-1,
vascular cell adhesion molecule-1; Lp(a), lipoprotein (a); vWF, von
Willebrand factor.
Ko et al. Trials 2011, 12:10
http://www.trialsjournal.com/content/12/1/10
Page 2 of 8
target lesions. Lipid profiles, to include total cholesterol,
LDL, HDL, triglyceride, apolipoprotein A-1 and B, LDL
particle size and HDL subfractions, and biomarkers
associated with atherosclerosis, including high-sensitivity
C-reactive protein (hsCRP), oxidized LDL, VCAM-1,
von Willebrand factor (vWF) and lipoprotein (a) [Lp(a)],
will be measured at enrollment, and at 1- and 9-month
follow-up examinations. The trial algorithm is shown in
Figure 1. This is an investigator-initiated clinical trial
with grant support from Korea Otska Pharmaceutical
Co. Ltd (Seoul, Korea). Other than providing financial
support, the company is not involved in developing
study protocols or study processes, including site selec-
tion, management, and data collection and analysis. The
study is performed according to the principles of the
Declaration of Helsinki and according to common
guidelines for clinical trials (ICH-GCP). The authors are
solely responsible for the design and editing of this
paper and its final content. The trial protocol has been
approved by the local institutional review boards of each
patient-enrolling center, and has been registered at
http://www.clinicaltrials.gov (NCT01031667). Patient
information, blood samples, and IVUS, VH and coron-
ary angiogram images will be coded with the identifica-
tion number of this study; investigators are blinded to
patient identifying information, which has been replaced
with a coded number.
Study population and Randomisation
Patients more than 20 years of age who have had at
least one significant coronary artery stenosis requiring
PCI with stent implantation and one intermediate lesion
on a native coronary artery with luminal narrowing of
≥ 30% and ≤ 70% by visual estimation, and who also
meet all inclusion and exclusion criteria (Table 1) are
eligible for this study. Those who agree to participate in
the study and give written consent are randomised (1:1)
to either cilostazol and probucol combination therapy or
cilostazol monotherapy (control) using a web-based
online randomization system. The randomization is stra-
tified by enrolling site and the presence of diabetes in
order to ensure an even distribution between the two
groups of major factors that might contribute to the pri-
mary end point. After enrollment, all patients will
receive a starting dose of 20 mg simvastatin. The dose
of simvastatin will be adjusted to reach a target LDL
level of < 100 mg/dL. Concomitant use of other drugs
that interfere with serum lipid levels, such as niacin,
CETP or lipoprotein-associated phospholipase A2 (Lp-
PLA2) inhibitor, fenofibrate or omega-3, is not allowed.
Index intermediate lesion for evaluating plaque volume
An intermediate lesion is defined as a lesion with a
luminal narrowing ≥ 30% and ≤ 70% (estimated visually)
that does not require percutaneous coronary interven-
tion. One such lesion located in the proximal or mid
segment of coronary arteries is selected by the operator
as the index intermediate lesion. Intermediate lesions
that might prove difficult to evaluate by IVUS, such as
bifurcating lesions, heavily calcified lesions (> 90° arc),
and those in tortuous vessels with severe angulation are
avoided in the selection of an index lesion.
Percutaneous coronary intervention
All patients should be on chronic aspirin (100-325
mg/day) and clopidogrel (75 mg/day) therapy for ≥ 5
days or receive aspirin (250 mg) and clopidogrel (300-
600 mg) loading at least 12 hours before PCI. Unfrac-
tionated heparin will be administered according to
local standards of care (target ACT 250 sec) at a
dosage as per label instructions. The use of glycopro-
tein IIb/IIIa inhibitors will be left to the discretion of
the operator. The criteria for an index PCI target
lesion are a stenotic lesion with a stenosis diameter >
50% and lesion length ≤ 26 mm that can be covered
by a single stent. All PCI target lesions, including
additional lesions not established as index lesions, will
be treated with Zotarolimus-eluting stents (Endeavor
Sprint, Medtronic Vascular Inc, Santa Rosa, CA).
After implantation of stents, aspirin (100 mg/day) and
clopidogrel (75 mg/day) will be administered during
the period of study.
Intravascular Ultrasound and Virtual Histology
All IVUS imaging will be performed using a 20-MHz
2.9F, phased-array IVUS catheter (Eagle Eye, Volcano
Therapeutics, Rancho Cordova, CA) after first adminis-
tering nitroglycerin (200 mg). The IVUS catheter is
placed distal to the target lesion, and then pulled back
using a motorized pullback system at 0.5 cm/s. During
pullback, grayscale IVUS is recorded and raw radiofre-
quency data are captured at the top of the R wave for
reconstruction of the color-coded map by a VH-IVUS
data recorder (Volcano Therapeutics). For evaluation
of the index intermediate lesion, a segment at least
30 mm in length will be evaluated with IVUS and VH
at baseline and 9-month follow-up. The most severe
10-mm segment centered on the minimal lumen area
will be analyzed for plaque volume and plaque compo-
sition (fibrotic, fibrofatty, dense calcium, and necrotic
core components). The index PCI target lesion will be
evaluated for neointimal growth with grayscale IVUS
after PCI and at 9-month follow-up. IVUS evaluation
will include 5-mm segments proximal and distal to the
stent. IVUS and VH images will be analyzed by an
independent core laboratory (Cardiac Core Analysis
Laboratory at Stanford University Medical Center,
Stanford, CA).
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Laboratory assessment
Blood samples will be obtained after overnight fasting.
Serum lipids, apolipoproteins, hs-CRP, Lp(a), oxidized
LDL, VCAM-1, and vWF levels will be measured at a
central clinical laboratory (Seoul Clinical Laboratories,
Seoul, Korea). Serum total cholesterol, LDL, HDL, and
triglyceride levels will be measured using standard
enzymatic methods. Apolipoprotein A-1 and B concen-
trations will be measured by turbidimetric immunoas-
say methods. Serum oxidized LDL, VCAM-1, and vWF
levels will be measured using enzyme-linked immuno-
sorbent assays. Serum hsCRP and Lp(a) levels will be
measured using latex-enhanced turbidimetric immu-
noassays. The particle-size distribution of LDL isolated
by sequential flotation ultracentrifugation will be deter-
mined using a pore-gradient lipoprotein system (CBS
Scientific, CA) at the National Research Laboratory
for Clinical Nutrigenetics/Nutrigenomics, Yonsei
University, Seoul, Korea, as previously described [26].
Circulating HDL subfractions HDL2 and HDL3 will be
quantified after ultracentrifugation of serum at the
Laboratory of Nutritional Medicine/Nutrigenomics,
Sungshin Women’s University, Seoul, Korea, as pre-
viously reported [27].
Study end points
The primary end point is the change in the plaque
volume of index intermediate lesions between baseline
and 9-month follow-up.
The secondary end points include the following:
• Plaque composition change by VH
• Clinical outcomes (death, myocardial infarction,
target vessel revascularization)
• Neointimal volume obstruction at index PCI target
lesions
• Blood lipid composition (total cholesterol, LDL,
LDL particle size, HDL, HDL subfractions, apolipo-
protein A-1 and B)
• Biomarkers (hsCRP, VCAM-1, oxidized LDL, Lp
(a), vWF)
Statistical considerations
Sample size calculation
The calculation of the sample size was based on an in-
equality design and a two-sample, two-sided test.
Assuming a standard deviation of 8%, an a-level of 0.05
and a statistical power of 80%, 41 patients are required
Table 1 Patient Inclusion and Exclusion Criteria
Inclusion criteria
1. Male or female over 20 years of age
2. Clinical indication for coronary angiography
3. Presence of at least one significant coronary artery stenosis (>50%) requiring PCI with stent implantation and one intermediate lesion with
luminal narrowing of ≥30% and <70% by visual estimation on native coronary arteries.
4. Presence of at least one PCI target lesion (reference diameter 2.5~4 mm, lesion length ≤26 mm) with >50% diameter stenosis that can be
covered with a single Zotrolimus-eluting stent (Endeavor Sprint, Medtronic Vascular Inc, Santa Rosa, CA).
5. Able to understand and willing to provide written informed consent
Exclusion criteria
1. Intermediate lesions that might provide difficulty for IVUS evaluation because of following reasons: heavy calcification (>90° Arc), tortuous
vessel with severe angulation, total occlusion, or bifurcation lesions
2. Previous PCI in the last 6 months
3. Previous coronary artery bypass graft
4. Patients with AMI undergoing primary PCI or rescue PCI after thrombolysis
5. Cardiogenic shock
6. Inability to take adequate antiplatelet therapy (aspirin and clopidogrel)
7. Thrombocytopenia (platelet count <70 × 109/l)
8. Known hypersensitivity or contraindication to any of the following medications: Heparin, aspirin, clopidogrel, cilostazol, probucol, statin,
contrast media
9. History of severe ventricular arrhythmia
10. Significant QTc prolongation (≥470 ms) on electrocardiogram
11. Heart failure (New York Heart Association class III/IV) or left ventricular ejection fraction ≤35%
12. Familial hypercholesterolemia
13. Uncontrolled hypertriglyceridemia (>400 mg/dL)
14. Chronic renal failure with serum creatinine level ≥2 mg/dL
15. Severe liver disease or transaminase level ≥3 times the upper limit of normal.
16. Pregnancy or women at age of childbearing potential
An additional file “Figure 1” contains figure 1.
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for each group (combination therapy, cilostazol mono-
therapy) to demonstrate a 5% difference in the mean
plaque volume in a 10-mm segment with the greatest
disease severity of the index intermediate lesion. Making
allowance for a drop-out rate of 30% increases the num-
ber of patients required for each group to 59. The treat-
ment difference and standard deviation assumptions are
based on previous clinical and animal studies. Several
IVUS studies have successfully demonstrated the effect
of statins in reducing plaque volume. Yokoyama et al.
[22] showed a 3.2% reduction in plaque volume in
patients treated with atorvastatin (10 mg/day) for
6 months. The ASTEROID trial achieved about a 25%
reduction in the normalized total atheroma volume
using rosuvastatin (40 mg/day) for 24 months [28].
Recently, Tardif at al. [29] reported that a 12-month
therapy with succinobucol, an analog of probucol,
reduced the plaque volume of index lesions by 1.5%,
whereas the control group showed no significant change
in plaque volume. Notably, the results of an animal
study evaluating the antiatherogenic effects of cilostazol
and probucol showed that combination therapy was
more effective in reducing the size of atherosclerotic
lesions than was administration of either drug alone
[18]. For this reason, we expect that cilostazol and pro-
bucol combination therapy will be more potent in redu-
cing plaque volume than succinobucol, and hypothesize
that the combination therapy could achieve a reduction
in plaque volume 5% greater than that achieved by cilos-
tazol monotherapy.
Statistical analysis
All statistical analyses will be carried out by an indepen-
dent organization, ADM Korea Inc. All primary and sec-
ondary end points will be analyzed on a modified
intention-to-treat basis (all randomized subjects who
receive at least one dose of study drug and have IVUS
and VH measurements at baseline and at the study end
point). The primary efficacy analysis will be performed
using an analysis of covariance model, adjusting for
baseline values. If the data are not distributed normally,
a nonparametric analysis of covariance analysis will be
used. All continuous secondary efficacy variables will be
analyzed using similar methods. The composite end
point of cardiovascular events will be analyzed by com-
paring Kaplan-Meier event rates using a log-rank test.
Independent predictors of major adverse cardiac events
(MACE) were determined using a multiple logistic
regression analysis.
Trial Organization
Principal Investigator Won-Heum Shim, Division of
Cardiology, Severance Cardiovascular Hospital, Yonsei
University Health System, Seoul, Korea
Statistical analysis ADM, Korea Inc., Seoul, Korea
Core laboratory for IVUS and VH Peter J. Fitzerald
and Yasuhiro Honda, Cardiac Core Analysis Laboratory
at Stanford University Medical Center, Stanford, CA,
USA
Core laboratory for biomarkers Seoul Clinical Labora-
tories, Seoul, Korea
Core laboratory for LDL subfractions Jong Ho Lee,
National Research Laboratory for Clinical Nutrigenetics/
Nutrigenomics, Yonsei University, Seoul, Korea
Core laboratory for LDL subfractions Myoungsook Lee,
Laboratory of Nutritional Medicine/Nutrigenomics,
Sungshin Women’s University, Seoul, Korea
Data coordination and site management Novotech
Korea, Seoul, Korea
Discussion
SECURE has been designed to test the hypothesis that
combination therapy with cilostazol and probucol is
more effective in reducing plaque volume than cilostazol
monotherapy. The effectiveness of probucol against
atherosclerosis has been demonstrated in previous clini-
cal trials. In the Fukuoka Atherosclerosis Trial (FAST),
the patient group treated with probucol (500 mg/day)
showed significantly reduced intima media thickness in
the common carotid artery compared to the control
group [30]. In an IVUS substudy of the Canadian Anti-
oxidant Restenosis Trial (CART-2), significant athero-
sclerosis regression was observed in patients treated
with the probucol analog succinobucol, whereas no sig-
nificant change in plaque volume occurred in the pla-
cebo group [29]. In the Probucol Observational Study
Illuminating Therapeutic Impact on Vascular Events
(POSITIVE), long-term probucol treatment effectively
prevented secondary cardiovascular events in a higher-
cardiovascular-risk heterozygous familial hypercholester-
olemia population without causing severe adverse effects
[31]. Cilostazol has also demonstrated diverse anti-
atherogenic properties in previous studies [11-14].
Recent animal studies have suggested that probucol and
cilostazol may synergize in the prevention of athero-
sclerosis by suppressing inflammatory reaction and pro-
moting cholesterol efflux [18,19].
In the SECURE study, in addition to changes in pla-
que volume, we will also evaluate the potential of com-
bination therapy to stabilize coronary plaques by
altering their composition. Virtual Histology, a software
system that enables a spectral analysis of radiofrequency
backscatter IVUS, was recently developed to analyze pla-
que composition, providing information on fibrous,
fibrofatty, dense calcium, and necrotic core components
[20]. VH findings have been validated using various
human atherosclerotic plaque tissues [21]. Different sta-
tins and darapladip, a direct lipoprotein-associated
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phospholipase A(2) inhibitor, have shown coronary pla-
que-stabilizing effects by reducing the necrotic core
[22-25]. The SECURE study will also confirm whether
the combination therapy is superior to cilostazol alone
in decreasing neointimal hyperplasia after implantation
of a drug-eluting stent. Previous studies have shown
that both probucol and cilostazol are effective in pre-
venting restenosis after PCI with or without stent
implantation [2,10,32]. In addition, Sekiya et al. [17]
demonstrated that cilostazol and probucol combination
therapy reduced restenosis after stent implantation more
effectively than either cilostazol or probucol alone.
Another focus of the SECURE study is on changes in
lipid composition associated with probucol and cilosta-
zol combination therapy. Generally, high LDL and low
HDL cholesterol levels are regarded as major risk factors
for coronary artery disease. However, within LDL and
HDL cholesterols are subfractions with different particle
sizes and different roles in the metabolism of lipids
[33,34]. Although still controversial, small, dense LDL is
thought to be more atherogenic in conjunction with
other features of metabolic syndrome, such low HDL
and high triglyceride levels [33]. Generally, the larger tri-
glyceride-rich HDL2 subfraction is thought to confer
better protection against coronary artery disease than
the small HDL3 fraction [34]. In a recent trial, the
CETP inhibitor torcetrapib, which raised HDL-C levels
by approximately 70%, showed a paradoxical increase in
cardiovascular disease outcomes [35]. Thus, a simple
elevation of HDL cholesterol levels does not necessarily
translated into protection from atherosclerosis. Probucol
is thought to reduce HDL cholesterol by enhancing
reverse cholesterol transport through increased expres-
sion of the hepatic HDL-receptor SR-B1 and activation
of CETP [4-6]. Hepatic over-expression of SR-B1
increases hepatic uptake of HDL cholesterol resulting in
increased biliary excretion of cholesterol. Probucol is
known to increase the levels and activity of CETP [4,5].
Activation of CETP increases transfer of cholesterol
esters from HDL to triglyceride-rich lipoprotein particles
in exchange for triglyceride, thereby reducing the circu-
lating HDL cholesterol concentration. Whether CETP is
anti- or proatherogenic is currently not fully understood.
Potential antiatherogenic roles of CETP include HDL
remodeling, with increased efflux of lipid-poor apolipo-
protein A-I in exchange for cholesterol; and shuttling of
cholesteryl esters to apolipoprotein B-containing lipo-
proteins, namely LDL, intermediate density lipoprotein
(IDL), and very low density lipoprotein (VLDL), for
excretion by the liver. In the SECURE study, we will
investigate lipid parameters, such as LDL and HDL sub-
fractions, and apolipoprotein A1 and B, as well as total
cholesterol, triglyceride, HDL, and LDL. In addition, we
will evaluate the effects of probucol and cilostazol com-
bination therapy on the atherosclerosis biomarkers, oxi-
dized LDL, VCAM-1, and vWF.
Possible major limitations of the SECURE study will
be the relatively small number of study population and
the short interval duration for follow-up IVUS study.
However, several small clinical studies have shown sig-
nificant plaque reduction with change of plaque compo-
sition despite relatively short period (6 or 12 months) of
follow-up [22,23,25]. Thus, if probucol combined with
cilostazol has strong antiatherosclerotic effects as shown
in previous clinical and experimental studies, we think
the SECURE study will be able to demonstrate them in
terms of the primary or secondary endpoints.
In conclusion, the SECURE study will be the first dou-
ble-blind, randomized, controlled multicenter clinical
trial using VH-IVUS to investigate the effects of probu-
col and cilostazol combination therapy on the progres-
sion and composition of coronary artery plaques.
Furthermore, the SECURE study will deliver important
information on the effects of combination therapy on
lipid composition and biomarkers related to athero-
sclerosis, thereby providing insight into the mechanisms
underlying the prevention of atherosclerosis progression
by cilostazol and probucol.
Trial registration number
National Institutes of Health Clinical Trials Registry
(ClinicalTrials.gov identifier #NCT01031667).
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